glycine has been researched along with Heart Failure in 30 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We therefore hypothesised that the consequences of creatine-deficiency in mice would be impaired running capacity, and exacerbation of heart failure following myocardial infarction." | 7.79 | Living without creatine: unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. ( Aksentijevic, D; Balaban, RS; Channon, KM; Clarke, K; Dawson, D; de Bono, JP; Hunyor, I; Lygate, CA; Medway, DJ; Neubauer, S; Phillips, D; Sebag-Montefiore, L; ten Hove, M; Watkins, H; Zervou, S, 2013) |
| "GXN could significantly maintain cardiac function and alleviate the progression of fibrosis in the kidney for HF mice, and the mechanisms of action were related to regulating redox metabolism of aspartate, glycine, serine, and cystine metabolism and SLC7A11/GPX4 axis in kidney." | 4.31 | Guanxining injection alleviates fibrosis in heart failure mice and regulates SLC7A11/GPX4 axis. ( Jia, P; Li, Y; Liu, Y; Long, K; Sun, T; Wang, C; Wang, S; Yang, Y; Zhang, H; Zhao, Y; Zheng, X; Zhi, W; Zhou, J, 2023) |
| "Calpain proteolysis contributes to the pathogenesis of heart failure but the calpain isoforms responsible and their substrate specificities have not been rigorously defined." | 4.02 | Calpain-2 specifically cleaves Junctophilin-2 at the same site as Calpain-1 but with less efficacy. ( Abel, ED; Chen, B; Ciampa, G; Hall, DD; Peng, T; Shi, Q; Song, LS; Wang, J; Zheng, D, 2021) |
| "We therefore hypothesised that the consequences of creatine-deficiency in mice would be impaired running capacity, and exacerbation of heart failure following myocardial infarction." | 3.79 | Living without creatine: unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. ( Aksentijevic, D; Balaban, RS; Channon, KM; Clarke, K; Dawson, D; de Bono, JP; Hunyor, I; Lygate, CA; Medway, DJ; Neubauer, S; Phillips, D; Sebag-Montefiore, L; ten Hove, M; Watkins, H; Zervou, S, 2013) |
| "The aim of this MERIT-HF sub-study was to ascertain whether this Glycine389 variant favourably influences outcome in heart failure similar to that observed with beta-blockers." | 3.72 | An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. ( Ball, SG; Balmforth, AJ; Cuthbert, R; de Boer, RA; Greenwood, D; Hall, AS; Maqbool, A; van Veldhuisen, DJ; White, HL, 2003) |
| "Homoarginine (hArg) is an endogenous, nonproteinogenic amino acid which differs from arginine by an additional methylene (CH2) group in the backbone." | 2.52 | Homoarginine in the renal and cardiovascular systems. ( Alesutan, I; Drechsler, C; Gaksch, M; Grübler, M; Hartaigh, BÓ; Lang, F; März, W; Meinitzer, A; Pilz, S; Tomaschitz, A; Verheyen, N; Voelkl, J, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (20.00) | 29.6817 |
| 2010's | 9 (30.00) | 24.3611 |
| 2020's | 5 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Ciampa, G | 1 |
| Zheng, D | 1 |
| Shi, Q | 1 |
| Chen, B | 1 |
| Abel, ED | 1 |
| Peng, T | 1 |
| Hall, DD | 1 |
| Song, LS | 1 |
| Iaremenko, OB | 1 |
| Iordanova, NK | 1 |
| Dudka, PF | 1 |
| Kuchmerovska, TM | 1 |
| Gao, T | 1 |
| Wang, R | 1 |
| Zhang, H | 2 |
| Zhao, F | 1 |
| Wang, C | 1 |
| Zhou, J | 1 |
| Wang, S | 1 |
| Liu, Y | 1 |
| Long, K | 1 |
| Sun, T | 1 |
| Zhi, W | 1 |
| Yang, Y | 1 |
| Zhao, Y | 1 |
| Zheng, X | 2 |
| Li, Y | 1 |
| Jia, P | 1 |
| Chen, Y | 1 |
| Zelnick, LR | 1 |
| Huber, MP | 1 |
| Wang, K | 1 |
| Bansal, N | 1 |
| Hoofnagle, AN | 1 |
| Paranji, RK | 1 |
| Heckbert, SR | 1 |
| Weiss, NS | 1 |
| Go, AS | 1 |
| Hsu, CY | 1 |
| Feldman, HI | 1 |
| Waikar, SS | 1 |
| Mehta, RC | 1 |
| Srivastava, A | 1 |
| Seliger, SL | 1 |
| Lash, JP | 1 |
| Porter, AC | 1 |
| Raj, DS | 1 |
| Kestenbaum, BR | 1 |
| Ng, R | 1 |
| Manring, H | 1 |
| Papoutsidakis, N | 1 |
| Albertelli, T | 1 |
| Tsai, N | 1 |
| See, CJ | 1 |
| Li, X | 1 |
| Park, J | 1 |
| Stevens, TL | 1 |
| Bobbili, PJ | 1 |
| Riaz, M | 1 |
| Ren, Y | 1 |
| Stoddard, CE | 1 |
| Janssen, PM | 1 |
| Bunch, TJ | 1 |
| Hall, SP | 1 |
| Lo, YC | 1 |
| Jacoby, DL | 1 |
| Qyang, Y | 1 |
| Wright, N | 1 |
| Ackermann, MA | 1 |
| Campbell, SG | 1 |
| Del Rio, R | 1 |
| Marcus, NJ | 1 |
| Schultz, HD | 1 |
| Pilz, S | 1 |
| Meinitzer, A | 1 |
| Gaksch, M | 1 |
| Grübler, M | 1 |
| Verheyen, N | 1 |
| Drechsler, C | 1 |
| Hartaigh, BÓ | 1 |
| Lang, F | 1 |
| Alesutan, I | 1 |
| Voelkl, J | 1 |
| März, W | 1 |
| Tomaschitz, A | 1 |
| Cauley, E | 1 |
| Wang, X | 1 |
| Dyavanapalli, J | 1 |
| Sun, K | 1 |
| Garrott, K | 1 |
| Kuzmiak-Glancy, S | 1 |
| Kay, MW | 1 |
| Mendelowitz, D | 1 |
| Jouni, H | 1 |
| Aubry, MC | 1 |
| Lacy, MQ | 1 |
| Vincent Rajkumar, S | 1 |
| Kumar, SK | 1 |
| Frye, RL | 1 |
| Herrmann, J | 1 |
| Koulaouzidis, G | 1 |
| Lyon, AR | 1 |
| Diercks, DB | 1 |
| Owen, K | 1 |
| Tolstikov, V | 1 |
| Sutter, M | 1 |
| Ramchandra, R | 1 |
| Hood, SG | 1 |
| Frithiof, R | 1 |
| McKinley, MJ | 1 |
| May, CN | 1 |
| Lygate, CA | 1 |
| Aksentijevic, D | 1 |
| Dawson, D | 1 |
| ten Hove, M | 1 |
| Phillips, D | 1 |
| de Bono, JP | 1 |
| Medway, DJ | 1 |
| Sebag-Montefiore, L | 1 |
| Hunyor, I | 1 |
| Channon, KM | 1 |
| Clarke, K | 1 |
| Zervou, S | 1 |
| Watkins, H | 1 |
| Balaban, RS | 1 |
| Neubauer, S | 1 |
| White, HL | 1 |
| de Boer, RA | 1 |
| Maqbool, A | 1 |
| Greenwood, D | 1 |
| van Veldhuisen, DJ | 1 |
| Cuthbert, R | 1 |
| Ball, SG | 1 |
| Hall, AS | 1 |
| Balmforth, AJ | 1 |
| PUGLIESE-CARRATELLI, M | 1 |
| CICALA, V | 1 |
| FRASCOLLA, N | 1 |
| GUDBJARNASON, S | 2 |
| TELERMAN, M | 2 |
| BING, RJ | 2 |
| CHIBA, C | 1 |
| WOLF, PL | 1 |
| HORKY, J | 1 |
| PLACER, Z | 1 |
| BORSOOK, ME | 1 |
| BORSOOK, H | 1 |
| Rupp, H | 1 |
| Rupp, TP | 1 |
| Maisch, B | 1 |
| Lionetti, V | 1 |
| Linke, A | 1 |
| Chandler, MP | 1 |
| Young, ME | 1 |
| Penn, MS | 1 |
| Gupte, S | 1 |
| d'Agostino, C | 1 |
| Hintze, TH | 1 |
| Stanley, WC | 1 |
| Recchia, FA | 1 |
| Wolk, R | 1 |
| Snyder, EM | 1 |
| Somers, VK | 1 |
| Turner, ST | 1 |
| Olson, LJ | 1 |
| Johnson, BD | 1 |
| Huang, TY | 1 |
| Pang, XQ | 1 |
| Ch'ang, HL | 1 |
| Levin, MC | 1 |
| Marullo, S | 1 |
| Muntaner, O | 1 |
| Andersson, B | 1 |
| Magnusson, Y | 1 |
| Kaku, I | 1 |
| Desmond, J | 1 |
| Mestyán, J | 1 |
| Fekete, M | 1 |
| Soltész, G | 1 |
| Járai, I | 1 |
| Gáti, I | 1 |
| Preisz, J | 1 |
| Doszpod, J | 1 |
| Verstraete, M | 1 |
| Olislaegers, P | 1 |
| Van Itterbeek, H | 1 |
| Waumans, P | 1 |
| Lust, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Medium-term Oral Guanidinoacetic Acid (GAA) Administration on Human Performance, Body Composition, and Metabolic Outcomes in Physically Active Men and Women[NCT01133899] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation[NCT01719367] | 38 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol. (NCT01719367)
Timeframe: after 5minutes of exercise
| Intervention | beats per minute (Mean) |
|---|---|
| Atenolol: Ancestral Alleles | -10 |
| Atenolol: Variant Carriers | -13 |
After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol. (NCT01719367)
Timeframe: after 10 amd 15 minutes of exercise
| Intervention | beats per minute (Mean) | |
|---|---|---|
| After 10 minutes | After 15 minutes | |
| Atenolol: Ancestral Alleles | -11 | -25.5 |
| Atenolol: Variant Carriers | -19.7 | -35.2 |
2 reviews available for glycine and Heart Failure
| Article | Year |
|---|---|
Homoarginine in the renal and cardiovascular systems.
Topics: Amidinotransferases; Animals; Biomarkers; Cerebrovascular Disorders; Energy Metabolism; Glycine; Hea | 2015 |
Proteasome Inhibitors as a Potential Cause of Heart Failure.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Clinical Trials as Topic; Drug Approval; Early D | 2017 |
28 other studies available for glycine and Heart Failure
| Article | Year |
|---|---|
Calpain-2 specifically cleaves Junctophilin-2 at the same site as Calpain-1 but with less efficacy.
Topics: Animals; Arginine; Calpain; Disease Models, Animal; Glycine; Heart Failure; HEK293 Cells; Humans; Ma | 2021 |
Sex-related differences in plasma amino acids of patients with ST-elevation myocardial infarction and glycine as risk marker of acute heart failure with preserved ejection fraction.
Topics: Amino Acids; Female; Glycine; Heart Failure; Humans; Male; Prospective Studies; ST Elevation Myocard | 2022 |
Network pharmacology combined with metabolomics reveals the mechanism of Fuzi decoction against chronic heart failure in rats.
Topics: Animals; beta-Alanine; Chronic Disease; Coenzyme A; Diterpenes; Drugs, Chinese Herbal; Glycine; Glyo | 2022 |
Guanxining injection alleviates fibrosis in heart failure mice and regulates SLC7A11/GPX4 axis.
Topics: Animals; Chromatography, Liquid; Drugs, Chinese Herbal; Fibrosis; Glycine; Heart Failure; Mice; Rosm | 2023 |
Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Topics: Aged; Albuminuria; Chromatography, Liquid; Cohort Studies; Cresols; Female; Glomerular Filtration Ra | 2021 |
Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradation.
Topics: Adult; Arrhythmias, Cardiac; Calpain; Cardiomyopathies; Desmoplakins; Female; Genetic Predisposition | 2019 |
Inhibition of hydrogen sulfide restores normal breathing stability and improves autonomic control during experimental heart failure.
Topics: Alkynes; Analysis of Variance; Animals; Autonomic Nervous System; Blood Pressure; Carotid Body; Chem | 2013 |
Neurotransmission to parasympathetic cardiac vagal neurons in the brain stem is altered with left ventricular hypertrophy-induced heart failure.
Topics: Animals; Brain Stem; Disease Models, Animal; Excitatory Postsynaptic Potentials; GABAergic Neurons; | 2015 |
Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bo | 2017 |
Urinary metabolomic analysis for the identification of renal injury in patients with acute heart failure.
Topics: Aged; Biomarkers; Creatinine; Discriminant Analysis; Female; Gas Chromatography-Mass Spectrometry; G | 2012 |
The role of the paraventricular nucleus of the hypothalamus in the regulation of cardiac and renal sympathetic nerve activity in conscious normal and heart failure sheep.
Topics: Animals; Bicuculline; Female; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; Glycine; Glycin | 2013 |
Living without creatine: unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice.
Topics: Adenylate Kinase; Animals; Creatine; Exercise Tolerance; Female; Glycine; Guanidinoacetate N-Methylt | 2013 |
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study.
Topics: Adrenergic beta-Antagonists; Aged; Arginine; Blood Pressure; Female; Genotype; Glycine; Heart Failur | 2003 |
[Contribution to the study of the action of glycocol in heart disease].
Topics: Fabaceae; Glycine; Heart Diseases; Heart Failure; Humans | 1953 |
PROTEIN METABOLISM IN CARDIAC HYPERTROPHY AND HEART FAILURE.
Topics: Animals; Aortic Valve Stenosis; Carbon Isotopes; Cardiomegaly; Glycine; Heart Failure; Myocardium; P | 1964 |
MYOCARDIAL PROTEIN SYNTHESIS IN CARDIAC HYPERTROPHY.
Topics: Animals; Carbon Isotopes; Cardiomegaly; Glycine; Heart Failure; Muscle Proteins; Myocardium; Protein | 1964 |
[DIAGNOSTIC SIGNIFICANCE OF SERUM PEPTIDASE DETERMINATION IN BLASTOMATOUS DISEASES].
Topics: Blood; Clinical Enzyme Tests; Diagnosis, Differential; Endopeptidases; Glycine; Heart Failure; Human | 1965 |
Treatment of cardiac decompensation with betaine and glycocyamine.
Topics: Betaine; Biochemical Phenomena; Cardiovascular Diseases; Creatine; Glycine; Heart Failure; Humans | 1951 |
Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure?
Topics: Animals; Carnitine O-Palmitoyltransferase; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compou | 2005 |
Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure.
Topics: Animals; Blotting, Western; Cardiac Pacing, Artificial; Carnitine O-Palmitoyltransferase; Dogs; Enzy | 2005 |
Arginine 16 glycine beta2-adrenoceptor polymorphism and cardiovascular structure and function in patients with heart failure.
Topics: Apolipoproteins E; Biomarkers, Tumor; DNA Mutational Analysis; Female; Genetic Predisposition to Dis | 2007 |
A bumpy road to breakthroughs. The news: it's hard to beat today's cardiac treatments.
Topics: Animals; Atherosclerosis; Coronary Thrombosis; Diabetes Mellitus, Type 2; Ethics, Clinical; Glycine; | 2006 |
Prophylactic effect of reserpine in cardiac failure caused by monofluoroacetic acid derivatives.
Topics: Animals; Citrates; Glycine; Heart Failure; Myocardium; Rabbits; Reserpine | 1980 |
The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation.
Topics: Down-Regulation; Genotype; Glycine; GTP-Binding Proteins; Heart Failure; Humans; Metoprolol; Polymor | 2002 |
Study of the myocardial nucleic acids and proteins metabolism in experimentally induced cardiac hypertrophy and heart failure.
Topics: Animals; Body Weight; Carbon Isotopes; Cardiomegaly; Cell Nucleus; Cytoplasm; DNA; Female; Glycine; | 1968 |
Serum osmolality and plasma electrolytes in patients who develop dilutional hyponatremia during transurethral resection.
Topics: Absorption; Aged; Blood; Central Venous Pressure; Electrolytes; Glycine; Heart Failure; Humans; Hype | 1970 |
The postnatal changes in the circulating free amino acid pool in the newborn infant. 3. The plasma amino acid ratio in infants born after pregnancies complicated by toxaemia, placental infarction, impaired umbilical circulation and chronic maternal diseas
Topics: Amino Acids; Chronic Disease; Female; Glutamine; Glycine; Heart Defects, Congenital; Heart Failure; | 1971 |
Human plasma and plasma fractions as sources of factor VIII (antihaemophilic factor).
Topics: Antigens; Blood Preservation; Blood Volume; Chemical Precipitation; Citrates; Factor IX; Factor VIII | 1969 |